Hologic, Inc. (HOLX)
NASDAQ: HOLX · Real-Time Price · USD
58.81
+2.06 (3.63%)
At close: May 12, 2025, 4:00 PM
58.86
+0.05 (0.09%)
After-hours: May 12, 2025, 6:06 PM EDT
Hologic Revenue
Hologic had revenue of $1.01B in the quarter ending March 29, 2025, a decrease of -1.23%. This brings the company's revenue in the last twelve months to $4.03B, up 1.66% year-over-year. In the fiscal year ending September 28, 2024, Hologic had annual revenue of $4.03B, down -0.00%.
Revenue (ttm)
$4.03B
Revenue Growth
+1.66%
P/S Ratio
3.38
Revenue / Employee
$576,037
Employees
6,990
Market Cap
13.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 28, 2024 | 4.03B | -100.00K | -0.00% |
| Sep 30, 2023 | 4.03B | -832.40M | -17.12% |
| Sep 24, 2022 | 4.86B | -769.50M | -13.66% |
| Sep 25, 2021 | 5.63B | 1.86B | 49.14% |
| Sep 26, 2020 | 3.78B | 409.10M | 12.15% |
| Sep 28, 2019 | Pro | Pro | Pro |
| Sep 29, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 24, 2016 | Pro | Pro | Pro |
| Sep 26, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
HOLX News
- 6 days ago - Hologic: Soft Performance, But Cheap Enough - Seeking Alpha
- 11 days ago - Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Medical equipment maker Hologic lowers annual profit forecast on tariff uncertainty - Reuters
- 11 days ago - Hologic Announces Financial Results for Second Quarter of Fiscal 2025 - Business Wire
- 17 days ago - Cellulite Treatment Market Trends, Growth Opportunities and Shares 2025-2030; Featuring Key Players - Hologic (Cynosure), Merz Pharma, Syneron Medical, Zimmer Aesthetics & More - GlobeNewsWire
- 18 days ago - Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI - Business Wire
- 20 days ago - Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report - Business Wire
- 5 weeks ago - Wayde McMillan Elected to Hologic Board of Directors - Business Wire